Company / Net Income
Esperion Therapeutics, Inc. Net Income History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Net Income
-$22.7M
FY2025
5-year range
-$269.1M / -$22.7M
FY2021-FY2025
Trend
+56.2%
vs FY2024
Sector context
#72 of 216
Health Care
What the data says
At -$23M, Esperion Therapeutics, Inc.'s net income ranks #72 of 216 in the Health Care sector. Net Income has increased for 4 consecutive years, from -$269M in FY2021 to -$23M in FY2025.
Based on SEC 10-K filings.
-$23M in FY2025.
Improved from -$209M to -$23M over the past 2 years.
Health Care sector context is included.
Net Income over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
#72 of 216 in Health CareTop 33% of 216This company -$22.7M Sector average $454.3M
▼
-105.0% below sector average
Key checks
Key Insights
- Esperion Therapeutics, Inc.'s net income has grown for 4 consecutive years.
- In FY2025, net income increased 56.2% year-over-year.
- Ranks #72 out of 216 companies in the Health Care sector.
- Lowest net income in the period was in FY2021.
Company context
Key Data Points
- Altman Z-Score -1.60 (distress zone, below 1.8 threshold)
- Negative profit margin: -15.6%
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Net IncomeValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$22.7M | +56.2% |
| FY2024 | -$51.7M | +75.3% |
| FY2023 | -$209.2M | +10.4% |
| FY2022 | -$233.7M | +13.2% |
| FY2021 | -$269.1M | -87.5% |
| FY2020 | -$143.6M | -47.7% |
| FY2019 | -$97.2M | +51.9% |
| FY2018 | -$201.8M | -20.9% |
| FY2017 | -$167.0M | -122.7% |
| FY2016 | -$75.0M | -50.6% |
As of FY2025 · SEC 10-K · Updated Jul 2, 2026